| Target Price | $6.12 |
| Price | $5.83 |
| Potential |
4.97%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Galectin Therapeutics Inc. 2026 .
The average Galectin Therapeutics Inc. target price is $6.12.
This is
4.97%
register free of charge
$6.30
8.06%
register free of charge
$6.06
3.95%
register free of charge
|
|
| A rating was issued by 7 analysts: 6 Analysts recommend Galectin Therapeutics Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Galectin Therapeutics Inc. stock has an average upside potential 2026 of
4.97%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.76 | -0.50 |
| 2.70% | 34.21% | |
| P/E | negative |
3 Analysts have issued a Galectin Therapeutics Inc. forecast for earnings per share. The average Galectin Therapeutics Inc. EPS is
This results in the following potential growth metrics and future valuations:
Galectin Therapeutics Inc....
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 14 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 27 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 14 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 02 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 27 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 15 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


